Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday? (UPDATED) – Emergent BioSolutions (NYSE:EBS)

Editor’s note: This story has been updated to replace an incorrect content previously published.

Tuesday, Emergent BioSolutions, Inc. E-book The company received more than $250 million in a contract modification from the U.S. Department of Health and Human Services’ Office of Strategic Preparedness and Response (ASPR) to supply millions of doses of four medical countermeasure drugs.
These contract modifications will ensure a continued supply/stockpile of critical medical countermeasures to address biological threats and emergencies such as anthrax, smallpox, and botulism.
There are four awards:

• A contract modification worth $30 million this year to supply Cyfendus (adsorbed, adjuvanted anthrax vaccine).
• Cyfendus, formerly known as AV7909, is a two-dose anthrax vaccine for post-exposure prophylaxis in individuals over the age of 18. Funding for the new procurement will come from Emergent’s existing 10-year contract with the Biomedical Advanced Research and Development Authority.
• A contract modification worth $99.9 million this year to supply ACAM2000 (smallpox (vaccinia) vaccine live), which builds on Emergent’s existing 10-year contract with ASPR.
• Two new contract options totaling $122.9 million have been signed to supply VIGIV to the Strategic National Stockpile. [Vaccinia Immune Globulin Intravenous (Human)] Pharmaceuticals and BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] Supplies of pharmaceutical raw materials and pharmaceutical production are expected to commence this year through early 2025.
• VIGIV is used for complications of smallpox vaccination, and BAT is indicated for symptomatic botulism in adults and pediatric patients with confirmed or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G.
• Both agreements build on existing 10-year contracts between Emergent and ASPR.

Read next:

Price Trends: EBS shares were up 13.6% at $8.02 as of last check on Tuesday.

Photo credit: Unsplash